Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.
Morning Overview on MSN
Study links beta cell cholecystokinin to obesity-driven pancreatic cancer
Researchers have identified a specific hormone produced by pancreatic beta cells as a direct driver of obesity-linked ...
Money Talks News on MSN
New pancreatic cancer treatment tracks tumors through your entire body
Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in lab studies, though long-term safety in humans remains unknown.
Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune | Cancer ...
Obesity is known to increase the risk of many serious diseases, including diabetes, heart disease, and certain types of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results